Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises Umia Sweden and other owners in connection with the sale of Umia Stockholm to Sandbäckens

 Umia Stockholm AB was founded in 2016 by Jonas Hedlund, Rolf Danielsson, Ronnie Ketola and Göran Karlsson, and currently has around 60 employees and a turnover of SEK 190 million (2023). The company specialises in electricity, which accounts for 70 % of its business, and ventilation. As part of the acquisition, Umia Stockholm AB will be integrated into the Sandbäckens brand in the near future.
December 11, 2024

Vinge advises Pricer AB in connection with its issuance of senior unsecured bonds and early redemption

 Vinge advises Pricer AB (publ) in connection with its issuance of floating rate senior unsecured bonds of SEK 300 million within a framework of SEK 500 million and early redemption of existing bonds.
December 10, 2024

Vinge has assisted Boliden in the acquisition of the Neves-Corvo and Zinkgruvan mines from Lundin Mining

Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan mine in Sweden. The upfront cash consideration for the entities is USD 1,300 m plus contingent payments that can reach up to USD 150 m, on a cash and debt-free basis. The transaction, that considerably strengthens Boliden's mine production as well as internal zinc and copper concentrate supply, is subject to customary regulatory approvals.
December 10, 2024